Á¦59Â÷ ´ëÇѺñ¸¸ÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-09
±³À°ÀÏÀÚ : 2024-03-09
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼¿ï, ºñ½ºÅ¸È¦
±³À°ÁÖÁ¦ : Á¦59Â÷ ´ëÇѺñ¸¸ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѺñ¸¸ÇÐȸ
´ã´çÀÚ : ÃÖÀ±Áö
¿¬¶ôó : 02-6941-0878
À̸ÞÀÏ : obmichelin@kosso.or.kr
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, °¡Á¤ÀÇÇаú
Âü¼®¿¹»óÀÎ : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 27 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í "»çÀüµî·Ï: 30000¿ø/50000¿ø/60000¿ø/80000¿ø
ÇöÀåµî·Ï: 50000¿ø/70000¿ø/80000¿ø/100000¿ø
Çлý: 30000¿ø *ÇлýÁõÁöÂüÇʼö"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 07:30~08:20 Cutting edge care of pitavastatin with ezetimibe combination therapy ±è°æ¼ö(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 08:30~08:55 Novel (non-approved) incretin-based therapies under investigation ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 08:55~09:20 The Long and Winding Road: How long does it maintain the pharmacotherapy? ±èÁøÈ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 09:20~09:45 The beneficial effect of SGLT2i and Phentermine-Topiramate FDC combination therapy È«ÁØÈ(À»ÁöÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 1 09:45~10:00 ÅäÀÇ ¹ÚÁ¤È¯°íÇýÁø(ÇѾçÀÇ´ë °æºÏÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 10:00~10:10 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 10:10~10:35 Circadian rhythms, sleep, and obesity ÀÌ´Ù¿µ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 10:35~11:00 The impact of air pollution on metabolic diseases ±èÇöÁø(±¹¸³¾Ï¼¾ÅÍ)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 11:00~11:25 Atypical antipsychotics and appetite regulation strategies ¼ÕÁ¾¿ì(KAIST)
Åä·Ð 03¿ù 09ÀÏ VISTA 1 11:25~11:40 ÅäÀÇ Á¶À±Á¤¹èÀçÇö(´ë±¸°¡Å縯ÀÇ´ë °í·ÁÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 11:40~12:00 Á¡½É½Ã°£ ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 12:00~12:40 What¡¯s new in T2D? Dapa + Sita combination! Á¤Ã¢Èñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 12:40~13:20 Obesity and Insulin Resistance ÀÌ°ü¿ì(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 13:20~13:50 Implication of Ectopic Fat in People with Relatively Low BMI ÀÓ¼ö(¼¿ïÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 13:50~14:00 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 14:00~14:25 Efficacy and Safety of Once-Weekly Semaglutide Update ³²°¡Àº(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 14:25~14:50 Once-weekly Tirzepatide ¹èÀçÇö(°í·ÁÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 14:50~15:15 Daily oral GLP-1 receptor agonists ³ëÀº(ÇѸ²ÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 1 15:15~15:30 ÅäÀÇ À̽Âȯ ±èÈÖ½Â(°¡Å縯ÀÇ´ë Áß¾ÓÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 15:30~15:40 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 15:40~16:10 Serotonin and Metabolism ±è°æ°ï(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 16:10~16:35 ºñ¸¸°ú ³ÀÓ Á¤¼±È(¾Ð±¸Á¤ µÎ¹ø°º½ »êºÎÀΰú)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 16:35~17:00 Obesity and Polycystic Ovary Syndrome ±èÁøÁÖ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 17:00~17:25 ¼Ò¾Æºñ¸¸°ú ¼ºÁ¶¼÷Áõ, Á¶±â ºÎ½Å¼ºÀå¹ß»ý ¾ç¾Æ¶÷(¼º±Õ°üÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 1 17:25~17:40 ÅäÀÇ ¿À¹üÁ¶ ÀÌ°æ¾Ö(¼¿ïÀÇ´ë ÀüºÏÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 07:30~08:20 Cutting edge care of pitavastatin with ezetimibe combination therapy ±è°æ¼ö(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 08:30~08:55 Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity À¯½ÂÁø(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 08:55~09:20 The N-degron pathway mediates lipophagy: The chemical modulation of lipophagy in obesity and NAFLD ¹ÚÁÖ¿ø(ÀÌÈ¿©´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 09:20~09:45 HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides ±èÀº°æ(DGIST)
Åä·Ð 03¿ù 09ÀÏ VISTA 2 09:45~10:00 ÅäÀÇ ¼Ûµµ°æ ±èÇü¼®(ÀÌÈ¿©´ë Ãæ³²ÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 10:00~10:10 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 10:10~10:35 The Significance of Ascorbic Acid in Regulating Thermogenesis and Energy Metabolism À̺À±â(ºÎ°æ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 10:35~11:00 ANK-Binding Kinase 1 Serves as a Key Regulator of Hepatocyte Fitness in MAFLD ÇãÁø¿µ(¼°´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 11:00~11:25 How diets regulate MASH Development. Casp2-S1P: The new hepatic lipid regulator ±èÁÖ¿¬(ÇѾç´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 2 11:25~11:40 ÅäÀÇ ÀÌÇö½Â ±è¹Î¼ö(Ãæ³²ÀÇ´ë KIST)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 11:40~12:00 Á¡½É½Ã°£ ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 12:00~12:40 What¡¯s new in T2D? Dapa + Sita combination! Á¤Ã¢Èñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 12:40~13:20 Obesity and Insulin Resistance ÀÌ°ü¿ì(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 13:20~13:50 Implication of Ectopic Fat in People with Relatively Low BMI ÀÓ¼ö(¼¿ïÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 13:50~14:00 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 14:00~14:25 Hypertension and cardiovascular disease ±è°æÈñ(¼¼Á¾º´¿ø)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 14:25~14:50 Type 2 diabetes ¹ÚÇü±Ô(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 14:50~15:15 Weight loss and weight regain ±Ç¿µ±Ù(°í·ÁÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 2 15:15~15:30 ÅäÀÇ À̼º¹è ÀÌ»óÀÏ(¼¼Á¾º´¿ø Ãæ³²ÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 15:30~15:40 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 15:40~16:10 The Keys to Successful Nutrition Therapy for Persons with Obesity or Overweight ±èÀº¹Ì(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 16:10~16:35 Clinical Studies Using Standardized Data on Obesity and Metabolic Diseases ¿¬µ¿°Ç(°æÈñÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 16:35~17:00 Obesity Fact Sheet for 2023 Á¤¼ö¹Î(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 17:00~17:25 Obesity research using data from the National Health Insurance Service ÀÌ»ó¿(°æÈñÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 2 17:25~17:40 ÅäÀÇ ±è¼±¿µ ¹®ÁØÈ£(°æÈñÀÇ´ë ¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 07:30~08:20 Cutting edge care of pitavastatin with ezetimibe combination therapy ±è°æ¼ö(ºÐ´çÂ÷º´¿ø)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 08:30~08:55 Estimation of Ultra-processed Food Intake among Korean adults ¹Ú¼ÒÇö(ÇѸ²´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 08:55~09:20 Ultra-processed foods intakes and obesity ½ÉÁö¼±(¿¬¼¼´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 09:20~09:45 Ultra-processed foods intake and all-cause and cardiovascular mortality ÀÌ»ó¾Æ(°¿ø´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 3 09:45~10:00 ÅäÀÇ ÀÓÇöÁ¤ ±ÇÀ¯Áø(°æÈñ´ë ¿¬¼¼ÀÇ´ë ¿ëÀμ¼ºê¶õ½º)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 10:00~10:10 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 10:10~10:35 Circadian rhythm, obesity, and intermittent fasting ±Ç¿Àºó(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 10:35~11:00 Chrononutrition and Time-Restricted Eatings Effect on Metabolic Health ¼ÛÀ±ÁÖ(°¡Å縯´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 11:00~11:25 Time-Restricted Eating-Integrating the What with the When ÀÌ¿¬Èñ(¾ÆÁִ뺴¿ø)
Åä·Ð 03¿ù 09ÀÏ VISTA 3 11:25~11:40 ÅäÀÇ ±ÇÇõÅ ¼Û¼öÁø(¼¿ïÀÇ´ë Çѳ²´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 11:40~12:00 Á¡½É½Ã°£ ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 12:00~12:40 What¡¯s new in T2D? Dapa + Sita combination! Á¤Ã¢Èñ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 12:40~13:20 Obesity and Insulin Resistance ÀÌ°ü¿ì(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 13:20~13:50 Implication of Ectopic Fat in People with Relatively Low BMI ÀÓ¼ö(¼¿ïÀÇ´ë)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 13:50~14:00 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 14:00~14:25 From obesogenic womb to obese adolescents ±èÀçÇö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 14:25~14:50 Causal links between chemical exposures and obesity in childhood and adolescence ±è½ÅÇý(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 14:50~15:15 Obesogenic environment: How can government policy make a healthy environment for pediatric obesity? Á¤¼ÒÁ¤(°Ç±¹ÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 3 15:15~15:30 ÅäÀÇ È«¿ëÈñ ±èÁø¿í(¼øõÇâÀÇ´ë È÷Æ÷Å©¶óŸÀÇ¿ø)
ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 15:30~15:40 Break ( )
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 16:10~16:35 Potential restorative effects of exercise for peripheral skeletal neuropathy and bone loss in a high-fat diet-induced type II diabetes model À̽¿ë(ÀÎõ´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 16:35~17:00 Regular exercise can how effectively transform our cardiovascular and brain health? ÇϹμº(¼¿ï½Ã¸³´ë)
±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 17:00~17:25 Exploring In Vivo Metabolic Fluxes Behind Insulin Resistance: Therapeutic Role of Exercise and Essential Amino Acids ±èÀÏ¿µ(°¡ÃµÀÇ´ë)
Åä·Ð 03¿ù 09ÀÏ VISTA 3 17:25~17:40 ÅäÀÇ À̹Îö ¹®È¿¿(Â÷ÀÇ´ë ¼¿ï´ë)